ClinicalTrials.gg
CompletedNCT05795192Updated Mar 21, 2024

SB17170 Phase1 Trial in Healthy Volunteer

A Phase 1 interventional study of SB17170 and Placebo in Safety Issues, Tolerability and Pharmacokinetics, sponsored by SPARK Biopharma. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by SPARK Biopharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

This clinical trial aims to learn about the safety, tolerability, and pharmacokinetic properties of SB17170 and its active metabolite SB1703 in single and multiple oral administration in healthy adults.

The main questions it aims to answer are the safety, tolerability, and PK characteristics of SB17170 in healthy adults.

Read the detailed description

This clinical trial aims to learn about the safety, tolerability, and Pharmacokinetic properties of SB17170 and its active metabolite SB1703 in single and multiple oral administration in healthy adults.

The main questions it aims to answer are the safety, tolerability, and PK characteristics of SB17170 in healthy adults.

The second questions are

  • To explore biomarkers and evaluate pharmacodynamic properties with ex-vivo test and proteome assay for SB17170
  • To evaluate the effects of ethnic differences on the safety, tolerability, and pharmacokinetic properties of SB17170 in healthy Korean and Caucasian adults.
  • To evaluate the effect of food between Fast and high-fat meals on safety, tolerability, and pharmacokinetic properties of SB17170 in healthy adults.

The difference between SB17170 and placebo on safety, tolerability, and PK/PD properties will be evaluated.

02

Conditions studied

  • Safety Issues
  • Tolerability
  • Pharmacokinetics
  • Pharmacodynamics

Keywords

  • HMGB1
03

In context

Lead sponsor

SPARK Biopharma is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Korean or Caucasian adults between the ages of 19 and 50 as of the date of written consent
  • Subjects with a body weight of 55.0 kg or more at the time of screening and a (BMI) of 18.0 kg/m2 or more and less than 30.0 kg/m2
  • Written

Exclusion criteria

Exclusion Criteria:

  • Clinical significant medical history
  • Gastrointestinal disease or past history
  • or hypersensitivity to the components of drugs
  • Screening test , ALT > x 1.5 \< 60mL/min/1.73m2 interval > 450 ms Serologic test positive(, , )
  • SBP \<90 mmHg or >150 mmHg, DBP \<60 mmHg or > 100 mmHg
  • Drub abuse history
  • Administration of any OTC drug, Herbal drug, Investigational medication within 2weeks
  • Participation in other clinical trial within 6 months
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    SB17170 of 50mg, Single dose

    Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 50mg capsule, QD for 1 day(single).

    Drug: SB17170

  • Placebo comparator
    Placebo of 50mg, Single dose

    Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 50mg, QD for 1 day(single).

    Drug: Placebo

  • Experimental
    SB17170 of 150mg, Single dose

    Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 100mg and 50mg capsules, QD for 1 day(single).

    Drug: SB17170

  • Placebo comparator
    Placebo of 150mg, Single dose

    Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 100mg and 50mg capsules, QD for 1 day(single).

    Drug: Placebo

  • Experimental
    SB17170 of 250mg, Single dose

    Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg capsule, QD for 1 day(single).

    Drug: SB17170

  • Placebo comparator
    Placebo of 250mg, Single dose

    Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg capsule, QD for 1 day(single).

    Drug: Placebo

  • Experimental
    SB17170 of 500mg, Single dose, Food-effect

    Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 2 capsules, QD for 1 day(single). Food-effect test for the expected efficacy dose * 1st period without a meal * Wash out period more than 7 days * 2nd period with a high-fat meal

    Drug: SB17170

  • Placebo comparator
    Placebo of 500mg, Single dose, Food-effect

    Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 2 250mg 2 capsules, QD for 1 day(single). Food-effect test for the expected efficacy dose * 1st period without a meal * Wash out period more than 7 days * 2nd period with a high-fat meal

    Drug: Placebo

  • Experimental
    SB17170 of 1000mg, Single dose

    Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 4capsules, QD for 1 day(single).

    Drug: SB17170

  • Placebo comparator
    Placebo of 1000mg, Single dose

    Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 2 250mg 4 capsules, QD for 1 day(single).

    Drug: Placebo

  • Experimental
    SB17170 of 1500mg, Single dose

    Optional dose Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 6 capsules, QD for 1 day(single).

    Drug: SB17170

  • Placebo comparator
    Placebo of 1500mg, Single dose

    Optional dose Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg 6 capsules, QD for 1 day(single).

    Drug: Placebo

  • Experimental
    SB17170 of 250mg, Multiple dose for 7days

    Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 1 capsule, QD for 7 days(multiple).

    Drug: SB17170

  • Placebo comparator
    Placebo of 250mg, Multiple dose for 7days

    Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 1 capsule, QD for 7 days(multiple).

    Drug: Placebo

  • Experimental
    SB17170 of 500mg, Multiple dose for 7days

    Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 2 capsules, QD for 7 days(multiple).

    Drug: SB17170

  • Placebo comparator
    Placebo of 500mg, Multiple dose for 7days

    Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 2 capsules, QD for 7 days(multiple).

    Drug: Placebo

  • Experimental
    SB17170 of 1000mg, Multiple dose for 7days

    Optional dose Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 4 capsules, QD for 7 days(multiple).

    Drug: SB17170

  • Placebo comparator
    Placebo of 1000mg, Multiple dose for 7days

    Optional dose Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 4 capsules, QD for 7 days(multiple).

    Drug: Placebo

Interventions

  • Taking SB17170 orally once a day

  • DrugPlacebo

    Taking Placebo orally once a day

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Safety and Tolerability in healthy subjects

    Time frame: From Day 1 to Day 7 for Single dose, From Day 1 to Day 9 for Multiple dose

Secondary outcomes

  1. The Area Under the Curve from dosing to the time of the last measured concentration

    Pharmacokinetic parameter

    Time frame: Baseline 0hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour

  2. The area under the curve from time 0 extrapolated to infinite time(AUCinf)

    Pharmacokinetic parameter

    Time frame: Baseline 0hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour

  3. The maximum (or peak) serum concentration(Cmax)

    Pharmacokinetic parameter

    Time frame: Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour

  4. The time to reach Cmax(Tmax)

    Pharmacokinetic parameter

    Time frame: Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour

  5. The Half life(t1/2) of SB17170 and active metabolite

    Pharmacokinetic parameter

    Time frame: Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour

  6. The ratio of oral clearance(CL/F)

    Pharmacokinetic parameter

    Time frame: Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour

  7. The Renal clearance(CLR)

    Pharmacokinetic parameter

    Time frame: Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour

  8. The volume of distribution(vd/f)

    Pharmacokinetic parameter

    Time frame: Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour

  9. The ratio of unchanged drug to metabolite(Metabolic ratio)

    Pharmacokinetic parameter

    Time frame: Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour

  10. Compare the concentrations of TNF-α between the active and placebo groups

    Tumor Necrosis Factor-alpha human(TNF-α) as a Pharmacodynamic parameter

    Time frame: Baseline 0 hour, 1.5hour, 24hour,

  11. Compare the concentratiosn of Interleukin-6 between the active and placebo groups

    Interleukin-6 as a Pharmacodynamic parameter

    Time frame: Baseline 0 hour, 1.5hour, 24hour,

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Feb 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Apr 3, 2023
StartActual
May 24, 2023
Primary completionActual
Feb 29, 2024
CompletionActual
Mar 15, 2024
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05795192
Lead sponsor
SPARK Biopharma
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
May 24, 2023
Primary completion
Feb 29, 2024
Completion
Mar 15, 2024
Last update
Mar 21, 2024

Study contacts

SeungHwan Lee, M.D.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HMGB1 Inhibitor SB17170

Start the discussion